Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

被引：17

作者：

Orditura, Michele ^{[1
]}

Galizia, Gennaro ^{[2
]}

Napolitano, Vincenzo ^{[2
]}

Martinelli, Erika ^{[1
]}

Pacelli, Roberto ^{[3
]}

Lieto, Eva ^{[2
]}

Aurilio, Gaetano ^{[1
]}

Vecchione, Loredana ^{[1
]}

Morgillo, Floriana ^{[1
]}

Catalano, Giuseppe ^{[1
]}

Ciardiello, Fortunato ^{[1
]}

Del Genio, Alberto ^{[2
]}

Di Martino, Natale ^{[2
]}

De Vita, Ferdinando ^{[1
]}

机构：

[1] Univ Naples 2, Div Med Oncol, I-80131 Naples, Italy

[2] Univ Naples 2, Sch Med, Dept Clin & Expt Med & Surg F Magrassi e A Lanzar, Div Surg Oncol, I-80131 Naples, Italy

[3] Univ Naples Federico II, Sch Med, Div Radiotherapy, Naples, Italy

来源：

CANCER INVESTIGATION | 2010年 / 28卷 / 08期

关键词：

Esophageal cancer; Preoperative chemoradiotherapy; Cisplatin; Paclitaxel; POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; NEOADJUVANT CHEMORADIATION; PATHOLOGICAL ASSESSMENT; ENDOSCOPIC ULTRASOUND; RESPONSE EVALUATION; CHEMORADIOTHERAPY; SURVIVAL; PET; ADENOCARCINOMA;

D O I：

10.3109/07357901003630926

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

引用

页码：820 / 827

页数：8

共 39 条

[1] Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy [J].

Adelstein, DJ ;

Rice, TW ;

Rybicki, LA ;

Larto, MA ;

Ciezki, J ;

Saxton, J ;

DeCamp, M ;

Vargo, JJ ;

Dumot, JA ;

Zuccaro, G .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2032-2039

[2]

AJANI JA, 1995, SEMIN ONCOL, V22, P46

[3] ACTIVITY OF TAXOL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS [J].

AJANI, JA ;

ILSON, DH ;

DAUGHERTY, K ;

PAZDUR, R ;

LYNCH, PM ;

KELSEN, DP .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (14) :1086-1091

[4]

Blanke CD, 1999, SEMIN RADIAT ONCOL, V9, P43

[5] International survey on esophageal cancer: part II staging and neoadjuvant therapy [J].

Boone, J. ;

Livestro, D. P. ;

Elias, S. G. ;

Rinkes, I. H. M. Borel ;

van Hillegersberg, R. .

DISEASES OF THE ESOPHAGUS, 2009, 22 (03) :203-210

[6] Radiation and chemoradiation therapy for esophageal adenocarcinoma [J].

Bosset, JF ;

Lorchel, F ;

Mantion, G ;

Buffet, J ;

Chéhange, G ;

Bosset, M ;

Chaigneau, L ;

Servagi, S .

JOURNAL OF SURGICAL ONCOLOGY, 2005, 92 (03) :239-245

[7] Quantitative techniques in 18FDG PET scanning in oncology [J].

Castell, F. ;

Cook, G. J. R. .

BRITISH JOURNAL OF CANCER, 2008, 98 (10) :1597-1601

[8] Evolving role of 18F-fluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma [J].

Dam, Hung Q. ;

Manzone, Timothy M. ;

Sagar, Vidya V. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 15 (04) :733-+

[9] Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus - A phase II study [J].

De Vita, F ;

Di Martino, N ;

Orditura, M ;

Cosenza, A ;

Galizia, G ;

Del Genio, A ;

Catalano, G .

CHEST, 2002, 122 (04) :1302-1308

[10] The role of integrated computed tomography positron-emission tomography in esophageal cancer: Staging and assessment of therapeutic response [J].

Erasmus, Jeremy J. ;

Munden, Reginald F. .

SEMINARS IN RADIATION ONCOLOGY, 2007, 17 (01) :29-37

← 1 2 3 4 →